VERAXA Biotech AG (NASDAQ: VRXA) has appointed Christoph Erkel, Ph.D., as chief scientific officer, effective immediately, the company announced. Erkel, previously vice president of research and development, will lead the advancement of VERAXA's proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development. His prior leadership roles include positions at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company's oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA continues to build its pipeline of bispecific T cell engagers and antibody-drug conjugates (ADCs). The BiTAC platform is designed to enable the development of next-generation antibody-based therapeutics. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is focused on applying rigorous quality-by-design principles to its drug discovery process.
For more information, see the full press release at https://nnw.fm/cR1RS. Updates on VERAXA are available in the company's newsroom at http://nnw.fm/VRXA.
This leadership change is significant as it positions VERAXA to leverage Erkel's extensive background in T-cell engagers and antibody engineering to advance its BiTAC platform, which is central to the company's strategy for developing therapies against solid tumors. The successful progression of BiTAC candidates into clinical trials could address significant unmet needs in oncology, particularly for cancers that are difficult to treat with conventional approaches.
Erkel's appointment also signals continuity in VERAXA's research strategy, given his previous role as vice president of R&D at the company. The transition period with outgoing CSO Rick Austin is expected to ensure a smooth handover of ongoing programs. Investors will be watching closely for updates on pipeline milestones and clinical trial timelines.
